Kenalog

Triamcinolone acetonide, the active ingredient in Kenalog, is a glucocorticoid presented as an injectable formulation for intraarticular, intralesional, and intramuscular use. It is employed to reduce inflammation and immune response in various musculoskeletal and dermatologic conditions.

GNH USA supplies Kenalog as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant documentation for global distribution.

Kenalog (triamcinolone acetonide) is used in inflammatory and musculoskeletal disorders where glucocorticoid therapy is indicated. - Arthritis: reduces joint inflammation and pain, improving mobility. - Bursitis: diminishes bursal swelling and discomfort. - Tendonitis: alleviates tendon inflammation, facilitating functional recovery. - Dermatologic inflammatory conditions: suppresses skin inflammation such as eczema or psoriasis plaques.

Kenalog may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection‑site pain or tenderness. - Local bruising or swelling. - Transient elevation of blood glucose. - Mild skin thinning at the injection site. - Headache.

Serious or Rare Side Effects: - Adrenal suppression or insufficiency. - Severe systemic infection or sepsis. - Anaphylactic or severe hypersensitivity reactions. - Vision changes, including cataracts or glaucoma. - Cushingoid appearance with prolonged high‑dose use. - Osteonecrosis of bone.

When prescribing Kenalog, clinicians should observe several safety considerations. - Infection risk: assess for active infections before injection. - Blood glucose monitoring: observe for hyperglycemia, especially in diabetic patients. - Hypersensitivity: discontinue if allergic reaction occurs. - Dose minimization: use the lowest effective dose for the shortest duration. - Systemic fungal infection: avoid use in patients with uncontrolled systemic fungal disease. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Kenalog can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Live vaccines: concurrent use may suppress vaccine efficacy and increase infection risk. - Systemic CYP3A4 inhibitors (e.g., ketoconazole): may raise systemic glucocorticoid levels, heightening adverse effects. - Anticoagulants (e.g., warfarin): glucocorticoids can enhance anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - NSAIDs: combined use raises gastrointestinal ulcer risk. - Diuretics: may exacerbate hypokalemia caused by glucocorticoids. - Antidiabetic agents: glucocorticoid therapy may require dose adjustments to maintain glycemic control.